查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840819

肝病诊断市场按产品、疾病类型和最终用户划分 - 全球预测（2025-2032 年）

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肝病诊断市场规模将达到 275.7 亿美元，复合年增长率为 9.42%。

关键市场统计数据
基准年 2024 134.1亿美元
预计年份：2025年 146亿美元
预测年份 2032 275.7亿美元
复合年增长率 (%) 9.42%

全面说明不断变化的诊断格局，其中临床紧迫性、技术创新和政策正在重塑肝病检测和治疗路径。

开篇部分将读者置于一个快速发展的诊断生态系统中，在这个系统中，技术创新、临床需求和监管变革正在交汇融合，重新定义肝臟疾病的检测、分期和监测方式。非侵入性检测技术的进步、成像解析度的提高以及更灵敏的血液标记物的出现正在重塑临床路径，而医疗系统则在寻求能够缩短诊断时间并支持以价值为导向的医疗服务的诊断方法。因此，临床、商业和政策领域的相关人员必须重新评估传统方法，并考虑采用与现代医疗模式相契合的综合诊断演算法。

本导言概述了推动变革的核心力量，为后续的论述组装了基础：临床医生对可操作资讯的需求、患者对微创治疗方案的偏好，以及支付方对医疗效率和疗效的关注。此外，本导言也着重阐述了传统组织病理学与新兴技术之间的相互作用，并强调了策略规划、跨学科合作以及对实证医学投入的重要性，以加速技术应用并优化临床效用。

技术创新、临床重点以及不断变化的监管和报销压力将如何改变肝病诊断的交付模式

在技​​术、临床和商业性层面，肝病诊断格局正经历着多项变革性的转变。在技​​术层面，诊断方法正朝着微创或非侵入性方向发展，力求在确保诊断准确性的同时兼顾患者的舒适度，这些方法包括先进的影像技术、增强的实验室生物标誌物检测以及利用计算分析从现有数据流中提取新的信号。在临床层面，诊断重点正从偶发性诊断转向纵向疾病监测，以便早期疗育并进行更细緻的风险分层。

从商业性角度来看，诊断技术开发人员、影像供应商和实验室服务公司之间的伙伴关係正变得更加策略性，旨在提供整合解决方案而非单一产品。法律规范也不断发展以适应新型诊断技术，而支付方也越来越重视临床效用和成本效益的证据来做出报销决策。总而言之，这些变化有利于那些能够证明其拥有强大的临床检验、能够无缝整合到医疗服务路径中，并能为医疗服务提供者和支付方提供清晰价值主张的提案。

预测并管理关税调整对2025年诊断设备和试剂采购、供应链和实施计画的影响

关税等政策措施有可能为全球诊断价值链带来新的复杂性，尤其对于在生产和分销过程中跨境流动的零件和设备而言更是如此。在美国，2025年宣布的关税调整可能会影响诊断设备、成像硬体和专用试剂的采购经济效益，迫使製造商重新评估筹资策略，并促使供应商评估其总体拥有成本。此类调整可能会加速供应商整合，促进供应链区域化，并鼓励製造商与医疗系统签订长期合同，以稳定需求和价格。

除了采购环节，关税还可能影响新产品上市的投资时机，因为企业需要权衡在进口动态不断变化的市场中推出新产品的商业性可行性。服务提供者和诊断实验室可能会透过加强与本地製造商的伙伴关係或增加库存缓衝来应对短期价格波动。此外，资本密集影像升级的延迟可能会影响先进技术融入常规诊疗的速度，进而影响临床应用率。因此，制定一项结合供应链多元化、合约对冲以及向支付方证明价值的策略应对措施，对于减轻关税相关干扰的累积影响至关重要。

主导深度细分，将产品类型、疾病特异性诊断需求和最终用户工作流程连结起来，从而指导产品和临床策略。

市场区隔揭示了诊断创新技术的整合方向以及临床工作流程与产品功能之间的相互作用。在按产品进行市场细分时，切片检查技术仍然是组织切片检查的基础，其中腹腔镜、经皮和静脉切片检查切片检查针对不同的临床场景，满足不同的安全性要求和采样需求。虽然以丙胺酸转氨酶、天门冬胺酸转氨酶和γ-谷氨酰转肽酶为中心的检测方法仍是常规操作，但新型多重生物标记正在涌现，以提高特异性并用于长期监测。诊断影像技术，包括电脑断层扫描、MRI和超音波，也在不断发展，采用更高解析度、功能性影像序列和基于软体的定量分析技术，从而增强临床医生的解读能力。

依疾病类型细分，可以更清楚地展现急性肝炎、酒精性肝病、慢性肝炎、肝硬化、肝细胞癌和非酒精性脂肪性肝病的需求模式和临床需求，每种疾病都对应着独特的检测策略和后续治疗方案。诊断实验室优化高通量分析和检测方法验证；医院将多模态诊断整合到病患诊疗路径和流程中；研究机构则致力于生物标记的发现和临床检验。这些视角能够细緻地展现临床需求、技术适用性和应用场景，进而指南产品开发和商业化策略。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和差异化采用模式正在影响策略性市场进入和规模扩张决策。

美洲、欧洲、中东和非洲以及亚太地区的肝病诊断需求和创新路径正受到区域动态的影响，每个地区都有其独特的考量。在美洲，人们高度重视临床可扩展性和诊断技术与大型医疗保健系统的整合，强大的肿瘤学和肝病学研究网络推动了先进影像学和分子检测技术的早期应用。该地区的医疗保健系统也倾向于优先考虑能够奖励已证实的临床和经济价值的报销模式，这影响着新诊断技术的定位和应用。

欧洲、中东和非洲地区（EMEA）的法规环境和医疗基础设施各不相同，导致产品采纳率和打入市场策略也存在差异。拥有集中式卫生技术评估流程的国家需要强有力的临床证据，而寻求实用且经济高效的解决方案的国家则采纳速度更快。在亚太地区，对诊断能力的快速投资、非酒精性脂肪肝疾病负担的日益加重以及诊断产品生产能力的不断扩大，正在推动国内创新和出口导向生产。在所有地区，跨境合作、监管协调以及对当地临床工作流程的考量，对于产品的成功引进和规模化生产仍然至关重要。

仪器製造商、检测技术创新者、实验室网路和灵活的新兴企业之间的竞争行动和策略伙伴关係正在决定该行业的未来发展轨迹。

肝病诊断领域的企业活动涵盖了成熟的设备製造商、专业的检测方法开发商、临床实验室网路以及专注于利基生物标记创新的敏捷型新兴企业。现有的影像设备製造商和供应商不断利用装置量和服务关係，推出软体增强功能；而专业的检测方法开发人员则致力于开展临床检验研究并获得关键监管审批，以推动产品从研究用途走向临床应用。临床实验室则着重标准化、高通量以及与电子健康记录的整合，以从常规筛检和监测方案中取得检测量。

合作开发模式日益普及，检测技术创新者与实验室网路和影像供应商合作，达成共同开发契约，提供联合诊断服务。将临床检验工作与支付方合作结合的策略联盟，能够加速报销谈判和实际应用。同时，规模较小的公司通常瞄准临床细分领域，例如非侵入性纤维化评估或早期肿瘤检测，在扩大商业性版图之前先确立其临床效用。那些优先考虑互通性、严谨的证据生成和可扩展生产的製造商，更有可能在竞争和监管压力下保持成长。

这是一份切实可行的策略指南，旨在帮助诊断技术开发人员和医疗保健领导者加速临床应用、优化供应链弹性并确保报销机制的协调一致。

产业领导者若想在肝病诊断领域维持并扩大市场份额，应将商业策略与临床证据的产生和切实可行的部署计画结合。优先进行严谨的前瞻性研究，以证明其在真实世界中的临床效用，有助于加强医保报销谈判，并提升临床医师的信心。同时，透过与电子健康记录的无缝连接、标准化的报告格式以及决策支援演算法，将诊断结果整合到诊疗路径中，可以减少临床工作流程中的摩擦，并提高诊断技术的采纳率。

在营运方面，供应链多元化、寻求区域製造伙伴关係以及建立长期采购协议可以降低关税波动带来的风险。研发团队还应制定分阶段的市场进入计划，充分考虑当地的监管环境和支付方，并利用试点项目和当地意见领袖来推动市场发展。最后，与医院、诊断实验室和研究机构建立合作关係，有助于收集产品迭代所需的证据，并促进产品在临床上的广泛应用。

一种透明的、专家主导的调查方法，结合了相关人员访谈、临床指南一致性以及交叉检验的证据综合，以得出可操作的结论。

调查方法融合了定性和定量方法，以确保研究结果的稳健性、可重复性和临床有效性。主要资料收集包括对临床医生、实验室主任和行业高管进行结构化访谈，以了解实践模式、未满足的需求和实施障碍。专家意见与二级资讯来源（包括同行评审文献、监管文件和临床指南）进行三角验证，以检验临床结论并在标准治疗框架内解读新兴技术。

我们的分析流程强调透过证据综合，对多个资讯流进行交叉检验，重点在于临床效用、整合可行性和商业化准备。细分和映射将产品、疾病类型和最终用户背景进行匹配，以反映实际部署场景。我们的品质保证流程包括专家评审週期，以及透明地说明纳入标准、资料来源和假设的调查方法和资料来源。对于新兴技术，特别是那些缺乏长期结果数据的技术，我们会根据现有依证提出建议，同时承认其局限性，并指出需要进一步检验的领域。

本文综合阐述了各项策略要务，展现了实证创新、整合工作流程和弹性运作将如何决定肝病诊断领域未来的领导地位。

分析结果表明，肝病诊断领域正处于曲折点，技术进步、临床对微创检测的需求以及医疗保险报销政策的转变，共同创造了重要的策略机会。能够展现清晰的临床效用、无缝融入医疗服务提供者的工作流程并有效管理供应链和政策风险的公司，将占据主要企业。同时，采取务实方法进行检验和整合的医疗系统和实验室，也将从病患诊疗路径和营运效率的提升中获益。

未来，最具变革性的益处将来自于能够实现早期检测、更精准分期和纵向监测以指导治疗方案选择的诊断解决方案。要实现这一潜力，需要持续投资于临床证据、合作商业化模式以及能够应对区域和政策动态的适应性营运策略。积极进行跨伙伴关係并优先考虑以患者为中心的结果的相关人员，最有能力将诊断创新转化为更好的临床实践和更佳的健康结果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将非侵入性液态生物检体整合到常规肝病诊断通讯协定中，而不是进行影像学检查。
  • 推出一款由人工智慧驱动的影像分析工具，用于早期检测肝纤维化和脂肪肝
  • 扩展多标靶生物标记组合，以全面评估肝臟发炎和纤维化分期
  • 在基层医疗机构应用照护现场瞬时弹性成像设备监测慢性肝病进展
  • 开发可携式生物感测器平台，用于门诊患者肝功能生物标记的即时监测

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肝病诊断市场（依产品类型划分）

  • 切片检查技术
    • 切片检查肝臟切片
    • 经皮肝经皮切片检查
    • 静脉肝切片检查
  • 血液检查
    • 丙氨酸转氨酶试验
    • 天门冬胺酸转氨酶试验
    • γ-谷氨酰转肽酶试验
  • 内视镜检查
  • 影像诊断
    • 电脑断层扫描
    • MRI
    • 超音波

第九章 肝病诊断市场（依疾病类型划分）

  • 急性肝炎
  • 酒精性肝臟疾病
  • 慢性肝炎
  • 肝硬化
  • 肝细胞癌
  • 非酒精脂肪肝

第十章 肝病诊断市场（依最终用户划分）

  • 诊断实验室
  • 医院
  • 研究所

第十一章 各地区肝病诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 肝病诊断市场（依组别分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国肝病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Amgen Inc.
    • Argon Medical Devices, Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Boston Scientific Corporation
    • Cook Medical Incorporated
    • Echosens by Astor Partners Srl
    • Epigenomics AG
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • Hepatiq, Inc.
    • Hologic, Inc.
    • Horiba, Ltd.
    • Koninklijke Philips NV
    • Laboratory Corporation of America Holdings
    • Medtronic PLC
    • Merck & Co., Inc.
    • Perspectum Ltd.
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • Randox Laboratories Ltd.
    • Ri.Mos. Srl
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc.
Product Code: MRR-B9334AD6C587

The Liver Disease Diagnostics Market is projected to grow by USD 27.57 billion at a CAGR of 9.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.41 billion
Estimated Year [2025] USD 14.60 billion
Forecast Year [2032] USD 27.57 billion
CAGR (%) 9.42%

A comprehensive orientation to the evolving diagnostic landscape where clinical urgency, innovation, and policy are reshaping liver disease detection and care pathways

The opening section situates the reader in a rapidly evolving diagnostic ecosystem where technological innovation, clinical need, and regulatory change are converging to redefine how liver disease is detected, staged, and monitored. Advances in non-invasive testing, improvements in imaging resolution, and more sensitive blood-based markers are reshaping clinical pathways, while health systems seek diagnostics that reduce time-to-diagnosis and support value-based care. As a result, stakeholders across clinical, commercial, and policy domains must reassess legacy approaches and consider integrated diagnostic algorithms that align with contemporary care models.

This introduction frames the broader narrative by outlining the central forces driving change: clinician demand for actionable information, patient preference for less invasive options, and payer emphasis on care efficiency and outcomes. It highlights the interplay between traditional histopathology and emerging modalities, and sets expectations for the analysis that follows by underscoring the need for strategic planning, cross-disciplinary collaboration, and investment in evidence generation to accelerate adoption and optimize clinical utility.

How technological innovation, clinical priorities, and evolving regulatory and reimbursement pressures are jointly transforming liver disease diagnostics delivery models

Several transformative shifts are redefining the liver disease diagnostics landscape, spanning technological, clinical, and commercial dimensions. On the technological front, there is a pronounced move toward minimally invasive or non-invasive modalities that balance diagnostic accuracy with patient comfort, including refined imaging, enhanced lab-based biomarkers, and computational analytics that extract new signal from established data streams. Clinically, the emphasis is shifting from episodic diagnosis to longitudinal disease monitoring, enabling earlier intervention and more nuanced risk stratification.

From a commercial perspective, partnerships between diagnostic developers, imaging vendors, and laboratory services are becoming more strategic, aimed at delivering integrated solutions rather than point products. Regulatory frameworks are evolving to accommodate novel diagnostics, and payers are increasingly focused on evidence of clinical utility and cost-effectiveness to inform reimbursement decisions. Taken together, these shifts favor companies that can demonstrate robust clinical validation, seamless integration into care pathways, and clear value propositions for providers and payers.

Anticipating and managing the ripple effects of 2025 tariff adjustments on procurement, supply chains, and adoption timelines for diagnostic devices and reagents

Policy actions like tariffs can introduce new complexities into the global diagnostics value chain, particularly for components and instruments that travel across borders during manufacturing and distribution. In the United States, tariff changes announced in 2025 have the potential to influence procurement economics for diagnostic equipment, imaging hardware, and specialized reagents, creating pressure on manufacturers to reassess sourcing strategies and on providers to evaluate total cost of ownership. These adjustments may accelerate supplier consolidation, regionalize supply chains, and prompt manufacturers to negotiate long-term contracts with health systems to stabilize demand and pricing.

Beyond procurement, tariffs can affect investment timing for new product introductions, as companies weigh the commercial viability of launches in markets with altered import dynamics. Service providers and diagnostic laboratories may respond by intensifying local manufacturing partnerships or increasing inventory buffers to manage short-term pricing volatility. In addition, the ripple effects can influence clinical adoption rates where capital-intensive imaging upgrades are deferred, thereby shaping the pace at which advanced modalities diffuse into routine practice. Strategic responses that combine supply-chain diversification, contractual hedging, and value demonstration to payers will be critical to mitigating the cumulative impact of tariff-related disruption.

Deep segmentation-driven insights that connect offering types, disease-specific diagnostic needs, and end-user workflows to guide product and clinical strategy

Segmentation illuminates where diagnostic innovation is concentrated and how clinical workflows interact with product capabilities. When the market is parsed by offering, biopsy techniques remain foundational for definitive tissue diagnosis, with laparoscopic liver biopsy, percutaneous liver biopsy, and transvenous liver biopsy each serving distinct clinical scenarios tied to safety profile and sampling needs. Concurrently, blood-based tests are advancing beyond basic hepatic panels: assays centered on alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase continue to be routine, while multiplexed and novel biomarkers are emerging to improve specificity and longitudinal monitoring. Imaging diagnostics-spanning CT scan, MRI, and ultrasound-are evolving through enhanced resolution, functional imaging sequences, and software-driven quantification that augment clinician interpretation.

Disease-type segmentation further clarifies demand patterns and clinical imperatives across acute hepatitis, alcoholic liver disease, chronic hepatitis, cirrhosis, hepatocellular carcinoma, and non-alcoholic fatty liver disease, each driving distinct testing strategies and follow-up regimens. End-user segmentation identifies where innovation is operationalized: diagnostic laboratories optimize high-throughput analytics and assay validation; hospitals integrate multimodal diagnostics into patient pathways and procedural workflows; and research institutes advance biomarker discovery and clinical validation. Together, these lenses provide a granular view of clinical need, technology fit, and deployment contexts that should guide product development and commercialization strategies.

Regional dynamics and differentiated adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape strategic market entry and scale-up decisions

Regional dynamics shape both demand and innovation pathways in liver disease diagnostics, with distinct considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical practice emphasizes scalability and integration of diagnostics into large health systems, with strong oncology and hepatology research networks driving early adoption of advanced imaging and molecular assays. Health systems in this region also tend to prioritize reimbursement models that reward demonstrable clinical and economic value, influencing how new diagnostics are positioned and adopted.

The Europe, Middle East & Africa region exhibits heterogeneity in regulatory environments and healthcare infrastructure, which creates a patchwork of adoption rates and market access strategies. Countries with centralized health technology assessment processes demand robust clinical evidence, while others exhibit faster uptake for pragmatic, cost-effective solutions. In Asia-Pacific, rapid investment in diagnostic capacity, growing burden of non-alcoholic fatty liver disease, and expanding diagnostic manufacturing capabilities are catalyzing both domestic innovation and export-oriented production. Across all regions, cross-border collaboration, regulatory harmonization, and attention to localized clinical workflows remain essential for successful product introduction and scale-up.

Competitive behaviors and strategic partnerships among instrument makers, assay innovators, laboratory networks, and nimble startups that are defining industry trajectories

Company behavior in the liver disease diagnostics space is being shaped by a mix of established instrument manufacturers, specialized assay developers, clinical laboratory networks, and nimble start-ups focused on niche biomarker innovations. Incumbent imaging and instrument providers continue to leverage installed bases and service relationships to introduce software-enabled enhancements, while specialized assay developers pursue clinical validation studies and key regulatory clearances to move from research use to clinical adoption. Clinical laboratory operators emphasize standardization, throughput, and integration with electronic medical records to capture volume from routine screening and monitoring protocols.

Collaborative models are increasingly prevalent, with partnerships and co-development agreements linking assay innovators to lab networks or imaging vendors to create combined diagnostic offerings. Strategic alliances that align clinical validation efforts with payer engagement accelerate reimbursement conversations and practical adoption. Meanwhile, smaller companies often pursue targeted clinical niches-such as non-invasive fibrosis assessment or early tumor detection-to establish clinical utility before broadening their commercial footprint. Manufacturers that prioritize interoperability, rigorous evidence generation, and scalable manufacturing will be best positioned to sustain growth amid competitive and regulatory pressures.

Actionable strategic playbook for diagnostic developers and healthcare leaders to accelerate clinical adoption, optimize supply resilience, and secure reimbursement alignment

Industry leaders seeking to maintain or grow their presence in liver disease diagnostics should align commercial strategy with clinical evidence generation and pragmatic deployment plans. Prioritizing rigorous prospective studies that demonstrate clinical utility in real-world settings will strengthen reimbursement discussions and clinician confidence. At the same time, integrating diagnostic outputs into care pathways-through seamless electronic health record connectivity, standardized reporting formats, and decision-support algorithms-will increase adoption by reducing friction in clinical workflows.

From an operational perspective, diversifying supply chains, pursuing regional manufacturing partnerships, and cultivating long-term procurement agreements can mitigate exposure to tariff-induced volatility. Commercial teams should also develop tiered market entry plans that account for regional regulatory variance and payer landscapes, leveraging pilot deployments and local opinion leaders to build momentum. Finally, cultivating collaborative relationships with hospitals, diagnostic laboratories, and research institutions enables iterative product refinement and supports the evidence generation needed to sustain broad clinical uptake.

A transparent, expert-driven methodology combining stakeholder interviews, clinical guideline alignment, and cross-validated evidence synthesis to underpin actionable conclusions

The research methodology integrates qualitative and quantitative approaches to ensure findings are robust, reproducible, and clinically relevant. Primary data collection includes structured interviews with clinicians, laboratory directors, and industry executives to capture practice patterns, unmet needs, and adoption barriers. Expert advisory input is triangulated with secondary sources, including peer-reviewed literature, regulatory filings, and clinical guidelines, to validate clinical claims and interpret emerging technologies within standard-of-care frameworks.

Analytical procedures emphasize cross-validation across multiple information streams, with evidence synthesis focused on clinical utility, integration feasibility, and commercialization readiness. Segmentation mapping aligns offerings, disease types, and end-user contexts to reflect real-world deployment scenarios. Quality assurance processes include expert review cycles and methodological documentation that transparently describe inclusion criteria, data sources, and assumptions. Limitations are acknowledged, particularly where nascent technologies lack long-term outcome data, and recommendations are framed to reflect the current evidence base while identifying areas where further validation is needed.

Synthesis of strategic imperatives showing how evidence-driven innovation, integrated workflows, and resilient operations will determine future leadership in liver disease diagnostics

This analysis concludes that the liver disease diagnostics landscape is at an inflection point where technological progress, clinical demand for less invasive testing, and shifting reimbursement priorities converge to create significant strategic opportunities. Companies that can demonstrate clear clinical utility, integrate seamlessly into provider workflows, and manage supply-chain and policy risks will be positioned to lead. At the same time, health systems and laboratories that adopt a pragmatic approach to validation and integration will realize benefits in patient care pathways and operational efficiency.

Looking forward, the most transformative gains will arise from diagnostic solutions that enable earlier detection, more precise disease staging, and longitudinal monitoring that informs treatment choices. Realizing this potential requires sustained investment in clinical evidence, collaborative commercialization models, and adaptive operational strategies that respond to regional and policy dynamics. Stakeholders who embrace cross-sector partnerships and prioritize patient-centered outcomes will be best placed to translate diagnostic innovation into improved clinical practice and health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of noninvasive liquid biopsy assays into routine liver disease diagnostic protocols over imaging
  • 5.2. Implementation of AI-driven image analysis tools for early detection of hepatic fibrosis and steatosis
  • 5.3. Expansion of multitarget biomarker panels for comprehensive assessment of liver inflammation and fibrosis staging
  • 5.4. Adoption of point-of-care transient elastography devices in primary care settings to monitor chronic liver disease progression
  • 5.5. Development of portable biosensor platforms for real-time monitoring of liver function biomarkers in outpatient clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Disease Diagnostics Market, by Offering

  • 8.1. Biopsy Techniques
    • 8.1.1. Laparoscopic Liver Biopsy
    • 8.1.2. Percutaneous Liver Biopsy
    • 8.1.3. Transvenous Liver Biopsy
  • 8.2. Blood-Based Tests
    • 8.2.1. Alanine Transaminase Test
    • 8.2.2. Aspartate Transaminase Test
    • 8.2.3. Gamma-Glutamyl Transpeptidase Test
  • 8.3. Endoscopy
  • 8.4. Imaging Diagnostics
    • 8.4.1. CT Scan
    • 8.4.2. MRI
    • 8.4.3. Ultrasound

9. Liver Disease Diagnostics Market, by Disease Type

  • 9.1. Acute Hepatitis
  • 9.2. Alcoholic Liver Disease
  • 9.3. Chronic Hepatitis
  • 9.4. Cirrhosis
  • 9.5. Hepatocellular Carcinoma
  • 9.6. Non-Alcoholic Fatty Liver Disease

10. Liver Disease Diagnostics Market, by End-User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Liver Disease Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Liver Disease Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Liver Disease Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Abbott Laboratories
    • 14.3.2. Amgen Inc.
    • 14.3.3. Argon Medical Devices, Inc.
    • 14.3.4. Bayer AG
    • 14.3.5. Becton, Dickinson and Company
    • 14.3.6. Bio-Rad Laboratories, Inc.
    • 14.3.7. BioMerieux SA
    • 14.3.8. Boston Scientific Corporation
    • 14.3.9. Cook Medical Incorporated
    • 14.3.10. Echosens by Astor Partners S.r.l.
    • 14.3.11. Epigenomics AG
    • 14.3.12. F. Hoffmann-La Roche Ltd.
    • 14.3.13. Fujifilm Holdings Corporation
    • 14.3.14. Hepatiq, Inc.
    • 14.3.15. Hologic, Inc.
    • 14.3.16. Horiba, Ltd.
    • 14.3.17. Koninklijke Philips N.V.
    • 14.3.18. Laboratory Corporation of America Holdings
    • 14.3.19. Medtronic PLC
    • 14.3.20. Merck & Co., Inc.
    • 14.3.21. Perspectum Ltd.
    • 14.3.22. Qiagen N.V.
    • 14.3.23. Quest Diagnostics Incorporated
    • 14.3.24. Randox Laboratories Ltd.
    • 14.3.25. Ri.Mos. Srl
    • 14.3.26. Siemens Healthineers AG
    • 14.3.27. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 282. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 283. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 284. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 285. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 287. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. E